Hemostemix Inc
Hemostemix Inc., a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, which is in Phase II clinical trial for the treatment of vascular diseases, such as peripheral arterial disease, angina pectoris, and ischemia, as well as heart failure, ischemic and dilated cardiomyopat… Read more
Hemostemix Inc (HMTXF) - Net Assets
Latest net assets as of September 2025: $-3.46 Million USD
Based on the latest financial reports, Hemostemix Inc (HMTXF) has net assets worth $-3.46 Million USD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.34 Million) and total liabilities ($4.80 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-3.46 Million |
| % of Total Assets | -258.5% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | -4238.44% |
| Growth Volatility | 895.94 |
Hemostemix Inc - Net Assets Trend (2013–2024)
This chart illustrates how Hemostemix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hemostemix Inc (2013–2024)
The table below shows the annual net assets of Hemostemix Inc from 2013 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-7.20 Million | +2.27% |
| 2023-12-31 | $-7.37 Million | -8.90% |
| 2022-12-31 | $-6.77 Million | -28.10% |
| 2021-12-31 | $-5.28 Million | -380.92% |
| 2020-12-31 | $-1.10 Million | +72.84% |
| 2019-12-31 | $-4.05 Million | -929.26% |
| 2018-12-31 | $487.80K | -89.92% |
| 2017-12-31 | $4.84 Million | +239.73% |
| 2016-12-31 | $-3.46 Million | -2088.88% |
| 2015-12-31 | $174.08K | -94.86% |
| 2014-12-31 | $3.39 Million | +490.67% |
| 2013-12-31 | $573.87K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hemostemix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 5150264900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $58.68 Million | % |
| Total Equity | $-7.20 Million | 100.00% |
Hemostemix Inc Competitors by Market Cap
The table below lists competitors of Hemostemix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Western Bulk Chartering AS
PINK:WSSTF
|
$10.46 Million |
|
Cubtek Inc.
TWO:2252
|
$10.46 Million |
|
IMAGIS Co. Ltd
KQ:115610
|
$10.46 Million |
|
BALAXI PHARMACEUTICALS LIMITED
NSE:BALAXI
|
$10.46 Million |
|
Bittnet Systems SA
RO:BNET
|
$10.44 Million |
|
Republic Power Group Limited Class A Ordinary Shares
NASDAQ:RPGL
|
$10.44 Million |
|
Berkem Group SA
PA:ALKEM
|
$10.44 Million |
|
TBH Global Co Ltd
KO:084870
|
$10.44 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hemostemix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from -7,371,228 to -7,204,151, a change of 167,077.
- Net loss of 2,616,402 reduced equity.
- New share issuances of 2,452,496 increased equity.
- Other comprehensive income decreased equity by 1,487,187.
- Other factors increased equity by 1,818,170.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-2.62 Million | -36.32% |
| Share Issuances | $2.45 Million | +34.04% |
| Other Comprehensive Income | $-1.49 Million | -20.64% |
| Other Changes | $1.82 Million | +25.24% |
| Total Change | $- | % |
Book Value vs Market Value Analysis
This analysis compares Hemostemix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $0.19 | $0.07 | x |
| 2014-12-31 | $1.09 | $0.07 | x |
| 2015-12-31 | $0.05 | $0.07 | x |
| 2016-12-31 | $-1.03 | $0.07 | x |
| 2017-12-31 | $0.69 | $0.07 | x |
| 2018-12-31 | $0.03 | $0.07 | x |
| 2019-12-31 | $-0.27 | $0.07 | x |
| 2020-12-31 | $-0.03 | $0.07 | x |
| 2021-12-31 | $-0.09 | $0.07 | x |
| 2022-12-31 | $-0.10 | $0.07 | x |
| 2023-12-31 | $-0.09 | $0.07 | x |
| 2024-12-31 | $-0.05 | $0.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hemostemix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-336.28%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -268.44% | 0.00% | 0.00x | 1.42x | $-1.60 Million |
| 2014 | -127.82% | 0.00% | 0.00x | 1.16x | $-4.67 Million |
| 2015 | -2289.23% | 0.00% | 0.00x | 4.58x | $-4.00 Million |
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | $-3.44 Million |
| 2017 | -81.34% | 0.00% | 0.00x | 1.10x | $-4.42 Million |
| 2018 | -1268.49% | 0.00% | 0.00x | 3.41x | $-6.24 Million |
| 2019 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.47 Million |
| 2020 | 0.00% | 0.00% | 0.00x | 0.00x | $-7.66 Million |
| 2021 | 0.00% | 0.00% | 0.00x | 0.00x | $-5.76 Million |
| 2022 | 0.00% | 0.00% | 0.00x | 0.00x | $-4.56 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.76 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | $-1.90 Million |
Industry Comparison
This section compares Hemostemix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hemostemix Inc (HMTXF) | $-3.46 Million | -268.44% | N/A | $10.45 Million |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |